UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 18, 2014
Date of Report (Date of earliest event reported)

TAPIMMUNE INC.
(Exact name of registrant as specified in its charter)

Nevada	**000-27239**	**88-0277072**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1551 Eastlake Avenue East, Suite 100, Seattle, WA	**98102**
(Address of principal executive offices)	(Zip Code)

(206) 504-7278
Registrant's telephone number, including area code

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02 Unregistered Sale of Equity Securities

The information provided in Item 8.01 of this Form 8-K is incorporated by reference in this Item 3.02.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The information set forth below under Item 8.01 is hereby incorporated by reference into this Item 5.03.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The information set forth below under Item 8.01 is hereby incorporated by reference into this Item 5.07.

Item 8.01 Other Events

Press Release Discussing Data from Phase I Clinical Trial

On March 3, 2014, we released a press release reporting that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. A copy of that press release is included as an exhibit to this current report on Form 8-K.

Corporate Actions

In our Information Statement filed on a Definitive Schedule 14-C with the U.S. Securities and Exchange Commission on January 28, 2014 and subsequently mailed to the non-objecting beneficial owners of our stock, we noticed our stockholders of certain actions that had been approved by our directors and a majority of our stockholders. These actions were approved by our directors, and were approved by holders of our capital stock, representing approximately 65% of all of the votes of our outstanding capital stock in a written consent in lieu of an Annual Meeting (the "Written Consent") on January 10, 2014. The approved corporate actions were to:

- enact a reverse stock split whereby every 100 shares of common stock held by a stockholder were to be exchanged for one share of our common stock with any fractional shares to be rounded up to the nearest whole share (the "Reverse Stock Split") and

- amend our Articles of Incorporation to increase our authorized share capital from 150,000,000 shares of common stock and 5,000,000 shares of preferred stock to 500,000,000 shares of common stock and 5,000,000 shares of preferred stock ("Amendment").

We filed with the Nevada Secretary of State a Certificate of Change Pursuant to NRS 78.209 to enact the Reverse Stock Split on February 18, 2014. As a result, the number of outstanding shares of our common stock was reduced on October 10, 2013 from 146,571,139 shares to approximately 1,465,711 shares. The respective relative voting rights and other rights that accompany the common stock were not altered by the Reverse Stock Split, the number of shareholders was not altered by the Reverse Stock Split and the common stock will continue to have a par value of $0.001 per share.

We filed with the Nevada Secretary of State a Certificate of Amendment to our Articles of Incorporation to enact the Amendment on February 20, 2014. As a result, the number of shares of common stock that we are authorized to issue increased from 150,000,000 to 500,000,000. The amendment neither affected the par value of our common stock, $0.001 per share, or the number of shares of preferred stock that we are authorized to issue, 5,000,000 shares.

Preferred Stock

Pursuant to our Articles of Incorporation, we are authorized to issue up to 5,000,000 shares of preferred stock. Our Board of Directors approved the creation of a class of up to 1,500,000 preferred stock, par value $0.001, called Series B Convertible Preferred Stock, and on February 18, 2014, we filed a Certificate of Designation for this class of stock with the Nevada Secretary of State. Under the terms of the Certificate of Designation, the Series B Convertible Preferred Stock:

- rank pari passu to the common stock with respect to rights on liquidation, winding up and dissolution;
- have no dividend rights except as may be declared by the Board in its sole and absolute discretion;
- shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock; and
- shall automatically convert into shares of common stock upon the occurrence of a reverse stock split of the Corporation's common stock in which every 100 shares of the Corporation's common stock outstanding at the time that this certificate of designation was filed with the Secretary of State of Nevada is exchanged for one share of the Corporation's common stock, with each share of Series B Convertible Preferred Stock converting into seven shares of the Corporation's common stock (such number to be after the 100:1 reverse stock split).

Debt conversions and stock issuances

We greatly reduced the debt outstanding on our balance sheet by converting debt into shares of our preferred stock, which in turn converted into shares of our common stock upon the occurrence of the Reverse Stock Split pursuant to applicable certificates of designation. On January 7, 2014, we filed a certificate of designation to create up to 1,250,000 shares of Series A Convertible Preferred Stock. Between January 7, 2014 and February 18, 2014, we converted debt totaling approximately $3,497,570 into 874,393 shares of Series A Convertible Preferred Stock. Upon the occurrence of the Reverse Stock Split on February 18, 2014, the Series A Convertible Preferred Shares converted into approximately 4,371,964 shares of common stock. Also on February 18, 2014, approximately $1,376,946 of outstanding debt converted into 1,376,946 shares of Series B Convertible Preferred Stock, which in turn converted into approximately 8,512,900 shares of common stock. As a result of these issuances, we have approximately 15,647,422 shares of our common stock currently issued and outstanding. These transactions were not registered under the Act in reliance on the exemption from registration in Section 4(2) of the Act, as a transaction not involving any public offering. We issued a press release on February 25, 2014 discussing these and other matters, a copy of which is attached as an exhibit to this current report on Form 8-K.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 (d)Exhibits.

Exhibit	Exhibit Description
3.1	Certificate of Amendment to Articles of Incorporation, dated February 22, 2010 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, dated February 26, 2010)
3.2	Certificate of Designation for Series B Convertible Preferred Stock, dated February 18, 2014
3.3	Certificate of Amendment to Articles of Incorporation, dated February 20, 2014
99.1	Press Release Dated March 3, 2014
99.2	Press Release Dated February 25, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TAPIMMUNE INC.

Date: March 3, 2014

By: /s/ Glynn Wilson
Name: Glynn Wilson
Title: Chairman and CEO

Exhibit 3.2

Certificate of Designation For
Nevada Profit Corporations
(Pursuant to NRS 78.1955)

1. Name of corporation: TapImmune Inc.

2. By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock.

Please see attached Certificate of Designation for the Series B Convertible Preferred Stock

3. Effective date of filing: (optional)

(must not be later than 90 days after the certificate is filed)

4. Signature:

/s/ Glynn Wilson
Signature of Officer

CERTIFICATE OF DESIGNATION

OF

TapImmune Inc.

Pursuant to Section 78.1955 of the

Nevada Revised Statutes

SERIES B CONVERTIBLE PREFERRED STOCK

On behalf of TapImmune Inc., a Nevada corporation (the "Corporation"), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Corporation (the "Board"):

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the "Articles of Incorporation"), there hereby is created, out of the five million (5,000,000) shares of preferred stock, par value $0.001 per share, of the Corporation authorized by Article III of the Articles of Incorporation ("Preferred Stock"), a series of Series B Convertible Preferred Stock, consisting of one million, five hundred thousand (1,500,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

The specific powers, preferences, rights and limitations of the Series B Convertible Preferred Stock are as follows:

1. Designation; Rank. This series of Preferred Stock shall be designated and known as "Series B Convertible Preferred Stock." The number of shares constituting the Series B Convertible Preferred Stock shall be one million, five hundred thousand (1,500,000) shares. Except as otherwise provided herein, the Series B Convertible Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu to (i) the common stock, par value $0.001 per share (the "Common Stock") and (ii) the Series A Convertible Preferred Stock, par value $0.001 per share.

2. Dividends. The holders of shares of Series B Convertible Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.

3. Liquidation Preference.

(a) In the event of any dissolution, liquidation or winding up of the Corporation (a "Liquidation"), whether voluntary or involuntary, the Holders of Series B Convertible Preferred Stock shall be entitled to participate in any distribution out of the assets of the Corporation on a seven (7) to one basis per share with the holders of the Common Stock and a one and four tenths (1.4) to one basis with the holders of the Series A Convertible Preferred Stock.

(b) A sale of all or substantially all of the Corporation's assets or an acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Corporation (a "Change in Control Event"), shall not be deemed to be a Liquidation for purposes of this Designation.

4. Voting. The holders of Series B Convertible Preferred Stock shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation's common stock, including the election of directors, and all other matters as required by law. This right is equal to that of the Series A Convertible Preferred Stock There is no right to cumulative voting in the election of directors. The holders of Series B Preferred Stock shall vote together with all other classes and series of common stock of the Corporation as a single class on all actions to be taken by the common stock holders of the Corporation except to the extent that voting as a separate class or series is required by law.

5. Conversion of Series B Convertible Preferred Stock.

(a) Automatic conversion. Upon the occurrence of a reverse stock split of the Corporation's common stock in which every 100 shares of the Corporation's common stock outstanding at the time that this certificate of designation was filed with the Secretary of State of Nevada is exchanged for one share of the Corporation's common stock, each share of Series B Convertible Preferred Stock shall automatically convert into seven (7) shares of the Corporation's common stock (such number to be after the aforementioned 100:1 reverse stock split), subject to adjustment as provided in this Section.

(b) No Fractional Shares. No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series B Convertible Preferred Stock. In lieu of any fractional share to which the Holder would otherwise be entitled, the Corporation shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series B Convertible Preferred Stock by the Corporation upon conversion of Series B Preferred Convertible Stock by such Holder.

(c) Stock Dividends, Splits, Combinations and Reclassifications. If the Corporation shall (i) declare a dividend or other distribution payable in securities, (ii) split its outstanding shares of Common Stock into a larger number, (iii) combine its outstanding shares of Common Stock into a smaller number (other than the 100:1 reverse stock split referred to in Section 5(a)), or (iv) increase or decrease the number of shares of its capital stock in a reclassification of the Common Stock including any such reclassification in connection with a merger, consolidation or other business combination in which the Corporation is the continuing entity (any such corporate event, an "Event"), then in each instance the Conversion Rate shall be adjusted such that the number of shares issued upon conversion of one share of Series B Convertible Preferred Stock will equal the number of shares of Common Stock that would otherwise be issued but for such Event.

(d) Issue Taxes. The converting Holder shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series B Convertible Preferred Stock.

IN WITNESS WHEREOF the undersigned has signed this Designation this February 18, 2013.

TapImmune Inc.

/s/ Glynn Wilson
Glynn Wilson
Chief Executive Officer and Director

Exhibit 3.3

Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

1. Name of corporation: TapImmune Inc.

2. The articles have been amended as follows: (provide article numbers, if available)

"3. The number of authorized shares is 500,000,000 shares of common stock and 5,000,000 preferred shares (the terms of which are to be determined at the sole discretion of the Board of Directors), each class with a par value of $0.001."

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise a least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation have voted in favor of the amendment is: 278,685,000 out of 428,685,000 (or 65.0%).

4. Effective date and time of filing: _____

5. Signature: /s/ Glynn Wilson

Exhibit 99.1

TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ breast cancer. Results Meet Management's Highest Expectations.

March 3 2014, Seattle WA, TapImmune Inc. (OTCQB: TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.

Importantly, this immune response data supports our contention that immune responses to our proprietary Class II antigens should be found in up to 84% of the patient population, making this potentially applicable to a much wider spectrum of patients when compared to other HER2/neu therapies; for example, Roche's Herceptin®. Herceptin, a $6+B per year drug (2013) and the current standard of care for this patient population treats less than 20% of the HER2/neu+ breast cancer patient population, leaving a very large market opportunity for a TapImmune vaccine approach.

Glynn Wilson, TapImmune CEO said, "This is the second positive endpoint in the on-going study and when taken together, the promising data currently presented along with the earlier reported interim safety analysis are tremendously encouraging and provides a clear scientific rationale for progressing to a Phase II Clinical Study." Moreover, Dr. Wilson stated that "The success in the current Clinical Trial supports the Company's three pronged therapeutic approach augmenting the ability of Class I killer T-cells to kill by enhancing the biological activity of relevant Class II T-helper cells along with augmenting the fundamentals of antigen presentation, making this one of the most comprehensive therapeutic vaccines in clinical development."

Dr. Keith Knutson, Director Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida, this trial's Principal Investigator, further commented that "The finding of specific immune responses in all patients has confirmed expectations that our approach is well reasoned, capable of reaching a broad population of breast cancer patients and is amenable to other HER2/neu indications such as colorectal and ovarian cancers. We are extremely pleased with the results thus far and expect to advance these studies to a Phase II Clinical Study in the near future."

Earlier the company had reported that the first endpoint to demonstrate safety on these patients was met.

In the current analysis of the first six patients, immune responses were stimulated against the HER2/neu antigens corresponding to T-cell epitopes mapping directly to both external and internal domains of the HER2/neu protein. Five patients showed immune responses against all four epitopes while one patient had immune responses to 3 epitopes. The use of these epitopes, discovered by Dr. Keith Knutson as naturally processed subdominant epitopes from breast cancer patient samples, illustrates an important focus of our vaccine development strategy, namely, to identify and amplify naturally occurring patient immune responses to cancer antigens.

Ultimately, TapImmune's therapeutic approach is designed to stimulate a long-lived Killer T-cell (CD8+, Class 1 HLA) mediated immune response resulting from the concomitant stimulation of one or more Helper T-Cell (CD4+ Class 2 HLA) responses. In contrast, Herceptin®, a monoclonal antibody directed to an external domain only of the HER2/neu protein, is not designed or intended to stimulate a Killer T-cell response. Furthermore, we believe that the use of TapImmune's candidate HER2/neu vaccine composition(s) could be expanded to include indications where there is a large market opportunity and unmet need, such as ovarian and colorectal cancers.

TapImmune is sponsoring this Phase I study and has an Exclusive Option to License the antigen technology at the end of Phase I. These studies are being conducted in breast cancer patients who have finished standard Herceptin®-based therapy and are at a high risk of disease recurrence.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.

Forward-Looking Statement Disclaimer*: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements*

Exhibit 99.2

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

SEATTLE, Feb. 25, 2014 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.

Dear Shareholders,

Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it. To address this, we now announce the completion of a corporate restructuring to attract the financial backing of some of the most respected names in life science to aid us in executing our product development plans and to provide fuel for our growth. For 2014, we have ambitious plans to advance and deepen our pipeline as we expand operations and explore strategic business development opportunities. Following is a partial summary of the progress we made over the last six months, as well as an overview of our objectives for 2014.

2013/2014 Highlights

To improve our profile in the investment community and place us on a stronger financial foundation, we have completed a capital restructure and successfully converted approximately $5,000,000 in secured and unsecured debt and payables eliminating the vast majority of the debt on our balance sheet. As the result of the conversion and a reverse stock split, we currently have approximately 16 million common shares outstanding. This provides a much more attractive capital structure, a strong balance sheet and allows the company to be valued at what we believe to be an extremely attractive entry point. To reflect the changes in our share structure, our ticker symbol will be TPIVD for the next 20 trading days.

In 2013, our HER2/neu clinical program continued with full recruitment of breast cancer patients, progression through initial safety checkpoint and demonstration of immune responses with interim data expected to be released in the near future. We also saw a major advancement in technology development in our own laboratories with “proof of concept” that our new and novel expression vector technology (PolyStart™) could provide a much greater signal for T-cells to kill abnormal cells and become a platform technology from which we can build out multiple applications and revenue streams. Additional data and information will be forthcoming as we attempt to further secure the intellectual property around this exciting technology advancement.

During 2013, results from our infectious disease program have opened several business development opportunities we expect to solidify by the end of 2014.

2014 Outlook

Consistent with our new financial structure, we plan to raise sufficient capital to progress our current clinical trials, license-in new clinical programs and expand our technology platforms well into 2015. We intend to also expand our patent portfolio and continue building a top-tier management team. As previously mentioned, the majority of our Company's prior debt has also been retired, further strengthening our overall financial position.

Over the next 12 months, we intend to advance and report on various clinical trials and R&D programs, thereby further strengthening the commercial potential of our comprehensive approach to immunotherapy that is designed to stimulate Helper T-cells and Killer T-cells and to enhance antigen presentation. All of the above considered, we believe makes TapImmune a leading innovator and a world-class immunotherapy company.

HER2/neu Breast Cancer Phase I/II clinical trials – Interim data analysis from our current Phase I trial has demonstrated safety. In addition, we plan to provide an interim analysis of specific T-cell immune responses associated with the first set of patients treated with 4 Class II antigens in the first quarter of 2014. We expect that this Phase I study will be formally completed this year. We plan to have discussions with the FDA on an IND amendment for a Phase I/II study that combines a novel Class I antigen along with the 4 Class II antigens. We expect this study to start in quarter four, and we will provide updates on our progress.

Deeper Pipeline – We have identified additional clinical assets that could enhance and deepen our clinical pipeline. We will provide more information on these opportunities as they develop.

PolyStart™ Technology – We will continue to secure the intellectual property portfolio surrounding our novel expression vector technology in the first quarter and expect to complete the preclinical testing in 2014 for subsequent incorporation into our HER2/neu clinical strategy and other pipeline developments.

Viral Disease Program – We will be reviewing our ongoing collaboration with Mayo Clinic on a novel smallpox vaccine in quarter one to determine progression to primate studies. Initial data from the studies looks very positive and a formal presentation of the findings will be made public when fully compiled. We expect that a decision to exercise the option to license this technology will be made in quarter two. We believe that the combination of novel peptide antigens plus our PolyStart™ technology is widely applicable to emerging viral threats. We expect to further this approach through collaborations, business development opportunities and non-dilutive financing sources.

Intellectual Property – In addition to licensing new intellectual property surrounding a new clinical program, we intend to file the initial patent for PolyStart™ and continue to develop this technology to solidify and enhance the patent position for a variety of cancers and viral diseases. We plan to be active in acquiring additional immunotherapy technologies that are synergistic with our current approach.

Strategic Collaborations – TapImmune will continue to develop strategic collaborations with leading institutions to: (i) leverage and enhance our research and development approaches, (ii) license new technologies and (iii) initiate additional clinical programs. We plan to strengthen our relationship with The Vaccine and Gene Therapy Research Institute of Florida and our collaborator Dr. Keith Knutson who recently relocated there from Rochester, MN.

Co-Development/Out-Licensing – We plan to seek a development partner for commercialization of our smallpox vaccine and viral disease program. While TapImmune will not be a company specializing in Bio-Defense; our technology platform fits extremely well with those that are developing and already provide contracted countermeasure vaccines for viral threats such as Smallpox.

Development Partnerships -- As we enter Phase II clinical trials and data are generated and published, we believe there will be significant interest from pharmaceutical companies. Because TapImmune is the only public company with a comprehensive approach to stimulate T-helper cells and T-killer cells and to enhance antigen presentation, we expect to attract significant interest in potential partnering and other strategic business development opportunities, particularly as our product candidates are intended to be simple injectable pharmaceuticals that are potentially synergistic with other approaches to cancer therapy.

Stock Market Uplisting – It is the strategic aim of TapImmune to meet the share price and shareholder equity criteria for listing its common stock on a national exchange, either Nasdaq or the New York Stock Exchange. As soon as we meet such criteria, we will take the necessary steps to up-list.

While we are currently focused on HER2/neu breast and ovarian cancer, our approaches can be explored for use with other cancers including colorectal and metastatic melanoma. Our focus on enhancing antigen presentation, in a prime and boost strategy, gives us the opportunity to make other approaches that are in development or already commercialized for cancer treatment, more effective and to establish TapImmune as a leading Immunotherapy company in the fight against cancer.

In closing, I thank you, our shareholders and investors, for helping to position TapImmune to build on its outstanding scientific foundation. In addition, I also extend our appreciation to our scientists and collaborators who have shared our vision and helped us make exceptional technical progress with minimal resources. Therefore I greatly look forward to reporting on our progress during 2014.

Sincerely,

Glynn Wilson, Ph.D.

Chairman and Chief Executive Officer

Tele: (206) 504-7280

For more information, please visit http://www.tapimmune.com.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (**T**ransporter associated with **A**ntigen **P**rocessing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.

Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.